Pfizer's Key Drug Walks A Tightrope

as the most likely new Pfizer compound to generate $1 billion in annual sales by 2015. Shares in Abbott Laboratories, whose top-seller Humira has the most to lose if tofacitinib is a success, popped 2%. After the market closed last night, Pfizer issued a...